QC
AKYA

Quadrature Capital’s Akoya BioSciences AKYA Stock Holding History

Quadrature Capital’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,891
Closed -$92.9K – 941
2024
Q2 		$92.9K Buy
+39,891
New +$127K ﹤0.01% 1039

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PCA
Peddock Capital Advisors Braintree, Massachusetts $501M AUM 29.8% 1-Year Est. Return

Quadrature Capital's AKYA Position: Q3 2024 in Review

Quadrature Capital sold out of Akoya BioSciences (AKYA) in Q3 2024, closing a stake of 39,891 shares — an estimated $92.9K sold.

Quadrature Capital first reported a position in AKYA in Q2 2024 and held it in 1 quarter. The position peaked at $92.9K in Q2 2024. 59 funds tracked by Wall St. Rank hold AKYA as of Q3 2024.

  • Quadrature Capital reported no remaining Akoya BioSciences position as of Q3 2024 after selling out during the quarter.
  • Quadrature Capital sold 39,891 Akoya BioSciences shares in Q3 2024, an estimated $92.9K.
  • Quadrature Capital first reported a position in Akoya BioSciences in Q2 2024 and held it in 1 quarter.
  • Quadrature Capital's Akoya BioSciences position peaked at $92.9K in Q2 2024.
  • 59 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2024.

Based on Quadrature Capital's 13F filing for Q3 2024, filed 14 Nov 2024.